Protocol Ledger

NCT07237256 · Phase III · RECRUITING

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Interventional Phase III clinical trial protocol NCT07237256 sponsored by UNICANCER in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-18 Enrollment: 3,902 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07237256
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,902 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07237256
Protocol FieldVerified Registry Value
NCT IdentifierNCT07237256
Consolidated Lead SponsorUNICANCER
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,902 participants (ESTIMATED)
Registered Start Date2025-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07237256
Hospital Research SiteLocationSite Profile
Institut BergonieBordeaux, FranceOpen Hospital Dossier ->
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI